Press Releases May 13, 2026 04:35 PM

Ethos Announces Early Lock-Up Release

Ethos Announces Partial Early Release of Shares from Lock-Up Period

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
LIFE

Ethos (Nasdaq: LIFE), a life insurance technology company, announced that 25% of eligible securities held by insiders and early investors will be released from lock-up restrictions and become eligible for sale on May 14, 2026. This partial early lock-up release could introduce approximately 5.1 million shares into the market. Additional releases are possible depending on future conditions.

Ethos Announces Early Lock-Up Release
LIFE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ethos satisfied conditions for partial early lock-up release, allowing 25% of eligible shares to be sold starting May 14, 2026.
  • Approximately 5.1 million Class A common shares will become eligible for sale, potentially increasing liquidity and trading volume.
  • Lock-up restrictions remain on remaining shares until July 27, 2026, with a potential further 25% release.
  • Sectors impacted include life insurance, insurtech, financial services, and public equity markets.

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- Ethos (Nasdaq: LIFE), a leading life insurance technology company on a mission to democratize access to life insurance, today announced the applicable price condition for a partial early lock-up release pursuant to the terms of the lock-up agreements entered into in connection with Ethos’s initial public offering has been satisfied. As a result, 25% of the eligible securities held by eligible holders as of February 15, 2026 (“Eligible Securities”) will be automatically released from the lock-up restrictions immediately prior to opening of trading on May 14, 2026 and may be sold into the public market.

The lock-up restrictions will continue to apply to all remaining shares subject to lock-up agreements until after the close of trading on July 27, 2026, subject to a potential additional release of an additional 25% of Eligible Securities, if the applicable conditions are satisfied.

The Company estimates that approximately 5.1 million shares of its Class A common stock will become eligible for sale in the public market in this partial early lock-up release at the open of trading on May 14, 2026.

About Ethos

Ethos is a leading life insurance technology company on a mission to protect families by democratizing access to life insurance and empowering agents at scale. With its robust three-sided technology platform, Ethos is transforming the life insurance experience for consumers, agents, and carriers alike. Ethos offers instant, accessible products and a seamless online process that requires no medical exams and just a few health questions; it eliminates traditional barriers, making it easier than ever for everyone to protect their families. Ethos is redefining how life insurance is bought, sold, and underwritten.

Learn more at ethos.com.

Investor Relations Contact:
Aaron Turner
ir@ethos.com

Press Contact:
Allyson Savage
press@ethos.com


Risks

  • Increased share supply from the lock-up release may put downward pressure on Ethos’ stock price temporarily.
  • Future lock-up releases depend on satisfaction of specified conditions, creating uncertainty around total shares becoming available.
  • Market reaction may be influenced by investor perception of insider or early investor selling, affecting stock volatility and pricing.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026